Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational, Multicentre, Prospective Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).

NCT03562819 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03562819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03562819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational, Multicentre, Prospective Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
August 16, 2018
Completion date
June 7, 2019
Enrollment
268 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc (non-small cell lung cancer)